Tomivosertib Suppresses Human DRG Neuron Hyperactivity in Radiculopathy

Study Background and Research Question

Neuropathic pain, typified by spontaneous or abnormal neuronal activity, remains a challenging and often insufficiently treated clinical problem. While animal models have provided insights into the mechanisms of neuropathic pain, direct studies on human sensory neurons, especially those implicated in pathologic pain states, are rare. Spontaneous activity (SA) in dorsal root ganglion (DRG) neurons has been identified as a key driver of neuropathic pain, particularly in conditions such as radiculopathy. Previous research has suggested that mitogen-activated protein kinase interacting kinases (MNKs) are involved in modulating neuron excitability; however, their role in human nociceptors remained speculative. The central question addressed by this study is whether pharmacological inhibition of MNK signaling using tomivosertib (eFT508) can directly suppress pathological activity in human DRG neurons derived from patients with radiculopathy.

Key Innovation from the Reference Study

The principal innovation lies in the direct testing of a clinically advanced MNK inhibitor, tomivosertib, on human DRG neurons exhibiting spontaneous activity associated with neuropathic pain. Unlike prior studies relying on animal models or indirect evidence, this work provides real-time, reversible modulation of human nociceptor excitability by targeting a specific intracellular signaling pathway. The rapid suppression of spontaneous activity and downstream molecular signaling by tomivosertib provides translationally relevant evidence for MNK as a therapeutic target in neuropathic pain disorders.

Methods and Experimental Design Insights

The research leveraged human DRG tissues obtained from 13 patients undergoing thoracic vertebrectomy for spinal cord or dorsal root compression, alongside samples from two organ donors without neuropathic pain. In vitro cultures of DRG neurons were established, with careful phenotyping to identify likely nociceptors based on cell size and action potential characteristics. Electrophysiological recordings were performed to measure spontaneous electrical activity and action potential properties before and after application of tomivosertib at 25 nM. Parallel biochemical assays assessed phosphorylation of eIF4E at serine 209, a canonical substrate of MNK, to confirm pathway inhibition. All procedures adhered to ethical guidelines and obtained informed consent.

Protocol Parameters

• Human tissue procurement: DRG neurons harvested during thoracic vertebrectomy surgeries from radiculopathy patients; donor controls included.
• Cell culture and identification: DRG neurons cultured and classified by size and action potential features to enrich for nociceptors.
• Tomivosertib treatment: 25 nM applied to cultured neurons; reversible effects assessed within minutes.
• Electrophysiological assessment: Spontaneous and evoked activity, action potential amplitude, and afterhyperpolarization measured pre- and post-drug.
• Biochemical validation: eIF4E Ser209 phosphorylation quantified in parallel after tomivosertib exposure.

Core Findings and Why They Matter

Tomivosertib rapidly and reversibly suppressed spontaneous activity in human DRG neurons that were identified as nociceptors, according to the reference study. Within minutes of exposure, the drug reduced both the frequency of spontaneous action potentials and the amplitude of individual action potentials. These electrophysiological effects were accompanied by a measurable reduction in eIF4E Ser209 phosphorylation, confirming effective MNK pathway inhibition in human sensory neurons.

Importantly, the observed changes—reduced action potential amplitude and altered afterhyperpolarization—suggest that tomivosertib modulates sodium and potassium channel activity downstream of MNK signaling. The rapid onset and reversibility of the effects underscore the potential for acute modulation of pain-related neuronal hyperexcitability in clinical settings. Given that tomivosertib is already in late-stage oncology trials, its safety profile and specificity make it a strong candidate for repurposing in neuropathic pain.

Comparison with Existing Internal Articles

While the current study focuses on the mechanistic underpinnings of neuropathic pain in human DRG neurons and the acute modulation of neuronal excitability via MNK inhibition, related internal articles emphasize the molecular techniques necessary for such investigations. For example, DNase I (RNase-free): Precision Endonuclease for DNA Removal details the enzyme's use in ensuring RNA sample purity and integrity—crucial for downstream transcriptomic or signaling analyses in neural tissues. Similarly, DNase I (RNase-free): Precision DNA Removal for RNA Extraction and DNase I (RNase-free) in Tumor Organoid Research highlight best practices for removing genomic DNA contamination during RNA extraction or in vitro transcription, both of which support accurate quantification of signaling pathway activation, like eIF4E phosphorylation, in pain research contexts.

Although the reference study's primary focus is on electrophysiological and biochemical readouts, the rigor of such analyses is often underpinned by the quality of molecular preparations—areas where ribonuclease-free DNase I remains indispensable in advanced research workflows.

Limitations and Transferability

Despite its strengths, the study is limited by the small cohort size (15 donors) and the ex vivo nature of the DRG neuron cultures, which may not fully recapitulate the in vivo microenvironment. In addition, while the rapid and reversible effects of tomivosertib on spontaneous activity are compelling, long-term consequences, potential compensatory mechanisms, and effects on non-nociceptor populations require further exploration.

Transferability to other forms of neuropathic pain or to broader patient populations will depend on future clinical trials. As with any approach relying on pharmacological kinase inhibition, potential off-target effects and long-term safety in the context of pain management must be thoroughly assessed. Nevertheless, the study provides a robust mechanistic rationale for targeting the MNK-eIF4E axis in human neuropathic pain.

Research Support Resources

For researchers investigating neuronal signaling, pain mechanisms, or gene expression in human or animal models, maintaining high-purity RNA is essential. Reagents such as DNase I (RNase-free) (SKU K1088) facilitate stringent removal of DNA contamination in RT-PCR and in vitro transcription workflows, supporting accurate quantification of molecular endpoints like eIF4E phosphorylation. Its cation-dependent activity and RNase-free formulation make it suitable for sensitive applications in neurobiology and pain research. For detailed protocols and best practices in DNA removal for RNA extraction, refer to the aforementioned internal articles. APExBIO's DNase I (RNase-free) can thus serve as a reliable tool in the preparation of high-quality samples for similar mechanistic studies.